# Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)

> **NCT00389987** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 300 (—)

## Conditions studied

- Complicated Intra-Abdominal Infections

## Interventions

- **DRUG:** MK0826, /Duration of Treatment : 8 Weeks
- **DRUG:** Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks

## Key facts

- **NCT ID:** NCT00389987
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09
- **Primary completion:** 2004-05
- **Final completion:** 2004-05
- **Target enrollment:** 300 (—)
- **Last updated:** 2017-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00389987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00389987, "Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00389987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*